baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Oxurion NV/ BE0003846632 /

2024-04-23 9:53:05 AM	Chg. 0.0000	Volume	Bid2024-04-23	Ask9:53:05 AM	High	Low
0.0001EUR	0.00%	7.16 mill. Turnover: 716	-Bid Size: -	0.0001Ask Size: 23.45 mill.	0.0001	0.0001

GlobeNewswire 04-15 Publication Annual Report – Annual Shareholders' Meeting

GlobeNewswire 04-15 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...

GlobeNewswire 04-11 Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

GlobeNewswire 04-10 Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully ...

GlobeNewswire 04-05 Postponement Annual Shareholders Meeting - Amendment financial calendar

GlobeNewswire 03-28 Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

GlobeNewswire 03-27 Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atl...

GlobeNewswire 03-26 Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atl...

GlobeNewswire 03-25 OXURION announces its presence at the Paris SmallCap event on March 28, 2024.

GlobeNewswire 03-22 Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

GlobeNewswire 03-21 Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atl...

GlobeNewswire 03-13 Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

GlobeNewswire 03-07 Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

GlobeNewswire 03-05 Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issu...

GlobeNewswire 03-04 Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atl...

GlobeNewswire 02-22 Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

GlobeNewswire 01-22 Oxurion Announces New Strategic Orientation to De-risk and Diversify

GlobeNewswire 01-19 Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atl...

GlobeNewswire 01-17 Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

GlobeNewswire 01-12 Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

GlobeNewswire 2023-12-28 Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of ...

GlobeNewswire 2023-12-01 Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

GlobeNewswire 2023-11-20 Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 i...

GlobeNewswire 2023-11-19 Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atla...

GlobeNewswire 2023-11-16 Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in...

Oxurion NV/ BE0003846632 /

If you wish to receive reply to your feedback, please provide your email address.